Sensex little changed; pharma stocks rise

Image
Reuters
Last Updated : Nov 02 2017 | 12:48 PM IST

By Tanvi Mehta

(Reuters) - Indian indexes were largely flat on Thursday as some company results including from Tech Mahindra Ltd disappointed investors, but gains in pharmaceutical shares lent some support.

Drug makers led by Divi's Laboratories Ltd staged a rally after the U.S. Food and Drug Administration lifted the import alert on one of the company's production plants.

Indian markets had hit record highs in the previous session, on continued optimism after the government's recent decision to inject more funds into state-run lenders.

"We've started on slightly uncertain footing, and yesterday's momentum is missing," said Anand James, chief market strategist, Geojit Financial Services.

"We need further cues to keep pushing indexes higher."

The broader NSE index was down 0.09 percent at 10,430.60 as of 0613 GMT, after rising marginally to hit a record high in early trade.

The benchmark BSE index was 0.06 percent lower at 33,581.24.

Among decliners, Tech Mahindra Ltd and JSW Energy Ltd fell after their Sept-quarter earnings report failed to please investors. Tech Mahindra fell as much as 5.7 percent while JSW Energy dropped as much as 4.7 percent.

However, the Nifty Pharma index rose as much as 3.6 percent to its highest since July 24, boosted by Divi's Labs. The U.S. health regulator said it would lift the import alert on the company's at Visakhapatnam unit in southern India and will close the warning letter it issued earlier.

Shares of Divi's Laboratories surged as much as 21 percent to their highest since Dec. 22, 2016.

State-run lenders continued their uptrend with the Nifty PSU bank index rising 0.9 percent. IDBI Bank Ltd and Indian Bank gained over 3 percent each.

(Reporting by Tanvi Mehta in Bengaluru; Editing by Sunil Nair)

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 02 2017 | 12:35 PM IST

Next Story